Circulating Type-1 Anti-Tumor CD4+ T Cells are Preferentially Pro-Apoptotic in Cancer Patients

Abstract

Cancer patients frequently exhibit a deficiency in Type-1 (but not Type-2 or regulatory) CD4(+) T cell responses against tumor-associated antigens (TAA), which may limit protection against disease progression or responsiveness to immunotherapy in these individuals. Since such deficiency was acutely evident in patients with active disease (AD), where chronic… (More)
DOI: 10.3389/fonc.2014.00266

Topics

8 Figures and Tables

Cite this paper

@inproceedings{Wesa2014CirculatingTA, title={Circulating Type-1 Anti-Tumor CD4+ T Cells are Preferentially Pro-Apoptotic in Cancer Patients}, author={Amy K. Wesa and Maja Mandi{\'c} and Jennifer L. Taylor and Stergios J. Moschos and John Munn Kirkwood and William W Kwok and James Harold Finke and Walter J. Storkus}, booktitle={Front. Oncol.}, year={2014} }